0001209191-20-035842.txt : 20200611
0001209191-20-035842.hdr.sgml : 20200611
20200611133019
ACCESSION NUMBER: 0001209191-20-035842
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200109
FILED AS OF DATE: 20200611
DATE AS OF CHANGE: 20200611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BESHAR LUKE M
CENTRAL INDEX KEY: 0001192128
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36694
FILM NUMBER: 20956797
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
STREET 2: 3RD FLOOR
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001359931
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 204580525
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 LITTLE WEST 12TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 646-844-0337
MAIL ADDRESS:
STREET 1: 1 LITTLE WEST 12TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: ArTara Therapeutics, Inc.
DATE OF NAME CHANGE: 20200110
FORMER COMPANY:
FORMER CONFORMED NAME: PROTEON THERAPEUTICS INC
DATE OF NAME CHANGE: 20060420
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2020-01-09
2020-01-13
0
0001359931
Protara Therapeutics, Inc.
TARA
0001192128
BESHAR LUKE M
C/O PROTARA THERAPEUTICS, INC.
1 LITTLE WEST 12TH STREET
NEW YORK
NY
10014
1
0
0
0
Stock Option (Right to Buy)
9.18
2020-01-09
4
A
0
12399
A
2028-07-11
Common Stock
12399
12399
D
Stock Option (Right to Buy)
9.18
2020-01-09
4
A
0
6676
A
2028-12-03
Common Stock
6676
6676
D
On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer.
Seven hundred seventy-four (774) of the Option Shares shall vest as of October 1, 2018, and the remaining Option Shares shall vest in forty five (45) approximately equal increments of two hundred fifty eight (258) whole Option Shares beginning on the first day of the fourth calendar month following the date of the grant (being November 1, 2018) and then on the first day of each of the next forty four (44) months thereafter (each a "Vesting Date"), if the Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being July 1, 2022), all of the Option Shares which had not vested by then will vest and become exercisable, and that the vesting of all then unvested Option Shares shall be accelerated upon a Change of Control.
Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share.
The shares subject to this option shall vest in forty eight (48) approximately equal increments of one hundred thirty nine (139) whole Option Shares beginning on the first day of the first calendar month following December 4, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a "Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then (being not less than 139 Option Shares) will vest and become exercisable.
Received in the Merger in exchange for a stock option to acquire 35,000 shares of ArTara Sub common stock for $1.75 per share.
/s/ Jesse Shefferman, Attorney-in-fact
2020-06-10